Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study

Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study

Background: Response to disease modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) is often heterogeneous. We aimed to identify types of disease activity trajectories following the initiation of a new biologic DMARD (bDMARD). Methods: Pooled analysis of nine national registries of p...

Full description

Bibliographic Details
Main Authors: D.S. Courvoisier, D. Alpizar-Rodriguez, J.E. Gottenberg, M.V. Hernandez, F. Iannone, E. Lie, M.J. Santos, K. Pavelka, C. Turesson, X. Mariette, D. Choquette, M.L. Hetland, A. Finckh
Format: Article
Language:English
Published: Elsevier 2016-09-01
Series:EBioMedicine
Subjects:
Abatacept
Rheumatoid arthritis
Disease activity
DAS28
Longitudinal data
Drug retention
Response rate
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396416303735

Internet

http://www.sciencedirect.com/science/article/pii/S2352396416303735

Similar Items